Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes

BACKGROUND: Emerging evidence supports that dihydroceramides (DhCer) and ceramides (Cer) contribute to the pathophysiology of insulin resistance and liver steatosis, and that their circulating concentrations are independently associated with cardiovascular outcomes. Circulating DhCer levels are incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Denimal, Damien, Bergas, Victoria, Pais-de-Barros, Jean-Paul, Simoneau, Isabelle, Demizieux, Laurent, Passilly-Degrace, Patricia, Bouillet, Benjamin, Petit, Jean-Michel, Rouland, Alexia, Bataille, Amandine, Duvillard, Laurence, Vergès, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158384/
https://www.ncbi.nlm.nih.gov/pubmed/37143040
http://dx.doi.org/10.1186/s12933-023-01845-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158384/
https://www.ncbi.nlm.nih.gov/pubmed/37143040
http://dx.doi.org/10.1186/s12933-023-01845-0

Ejemplares similares